Thu, Jul 31, 2014, 10:32 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Celldex Therapeutics, Inc. Message Board

  • whippersnapper65 whippersnapper65 Mar 9, 2013 10:09 PM Flag

    If a partnership is signed...

    Based on Marucci's comments about seeking the best deal possible and not entertaining any inferior proposals, if a partnership agreement is signed the terms will be so favorable for CLDX that it will cause CLDX's share price to double that day. That reality will also be on the minds of investors and buyers as the share price is bid up over the next several months. Imagine postponing your decision to buy CLDX because you are waiting for a pullback only to wake up one morning to news that a partnership agreement has been signed and watching CLDX open above $25 or $30 per share. Decisive investors will want to buy in now in order not to miss the boat, and that will continue to drive share price appreciation.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • whipper...ONE of the best Partnership deals signed I have witne$$ed personally was INFI!

      Go back and google the deal they signed a couples years ago w/ Mundi Pharma and Purdue-Frederick. Basically these TWO companies GAVE INFINITY a BLANK CHECK! It was based on the Genius and Maverick nature of Science Guru Julian Adams of Velcade Fame at MLNM another old holding of mine....Takeda bought up what CELGENE folks used to RIDICULE...I made BANK on it!

      I see CLDX doing the same eventually when the genuis of Drs. Davis/Kellor is realized! I know first hand about Tibor Kellor having visited the NJ labs a couple years ago as I was taken through animal research(my interest !) on my quest to learn what CLDX was doing! AM through out the Red Carpet for little OLD me...all was of Publicly stated nature/info...I tested their VERACITY too...they keep it CLOSE TO THE VEST!!!

      That's what U want in a good LT BIO play...HONESTY and Shrewd Busine$$ sense...CLDX is both!


      Sentiment: Strong Buy

    • Great post! I expect that there will be heavy pre-market trading on Monday.

      Sentiment: Strong Buy

    • Maybe on Monday we will get early results on DCVax-001. The volume and price change on Friday was dramatic.
      The three-year, randomized, placebo-controlled, Phase I trial, known as DCVax-001, will enroll 45 healthy HIV-uninfected volunteers in New York City. Investigators will evaluate both the safety and immunogenicity of the vaccine candidate administered at three different doses, along with a fixed dose of an experimental adjuvant called Poly ICLC (Hiltonol) that was designed to activate innate immune responses. The volunteers will receive three subcutaneous vaccinations of either the vaccine candidate or placebo over 12 weeks, and will then be monitored for 12 months.
      Researchers at Rockefeller have been working with Celldex Therapeutics, a biotechnology company headquartered in Massachusetts, on the development of the candidate vaccine. Celldex previously developed a vaccine candidate with a mAb fused to DEC-205 to target a tumor-associated antigen known as NY-ESO-1, but this is the first time an AIDS vaccine candidate has been constructed using this technology.
      Estimated Enrollment: 45
      Study Start Date: May 2010
      Estimated Study Completion Date: May 2013
      Estimated Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
      Principal Investigator: Sarah Schlesinger, MD The Rockefeller University

      Looks what’s coming at AACR!
      Characterization of the response of human T cells to an agonist human anti-CD27 mAb
      Monday, Apr 08, 2013, 1:00 PM - 5:00 PM
      Karuna Sundarapandiyan, Laura Vitale, Biwei Zhao, Thomas O'Neill, Henry Marsh, Venky Ramakrishna, Tibor Keler. Celldex Therapeutics, Inc., Phillipsburg, NJ
      APC targeting and maturation in the clinic
      Tuesday, Apr 09, 2013, 11:05 AM -11:25 AM
      Thomas A. Davis. Celldex Therapeutics, Clarksville, M.D

      Sentiment: Strong Buy

    • Yes, it is a win-win situation. It is stark screaming transparently clear that they co is in POSITION to select and choose. This alone is very rare for a "small biotech." Hence perhaps another "connection" to the PCYC scenario. It is as rare as a secondary offering at the fricken retail price (7.50) the previous day of close. And I will remind you that what you mentioned happened, indeed already on last trading session. Some Investors and idiot shorts anticipated that aw, the typical, typical no news CC of Thursday would bring this baby down and time for some profit taking. Yes, indeed! There was "some profit taking" but more three-card monty for a few hours bewtween hedge funds and others furiously attempting to drive price down. Shot down! Shot right back up! with twice the buying. Buying was excellent and solid that it closed slight down but immensely strongly. Next day, Friday BOOM! Shorts disposed of in one fell swoop. No time to catch breath. As all the coverage raised significantly (and I might add, as they had to, conservatively) their targets. Bottom line. This is an entirely different company AS IT NOW HAS SIGNIFICANT EXPOSURE. To get in at this price is to be able to double within relatively short period of time and willing to hold to end of 2013-2014 triple. Again We are looking at a PCYC appreciation...

      • 1 Reply to neshua10
      • Nice post. Celldex has positioned itself and thought out every angle of bringing their products to market and have established a very good investment for shareholders. I cannot think of another stock that I would prefer to own over Celldex. Congrats and thanks to Marucci, everyone involved in the product development process and the board of directors of Celldex....what a great job that they have done bringing us to this great position.

        Sentiment: Strong Buy

13.09-0.61(-4.45%)Jul 31 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Tesla Motors, Inc.
NasdaqGSThu, Jul 31, 2014 4:00 PM EDT
GoPro, Inc.
NasdaqGSThu, Jul 31, 2014 4:00 PM EDT